
Sign up to save your podcasts
Or


We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
By Retina Synthesis4.5
88 ratings
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

43 Listeners

18 Listeners

97 Listeners

112,586 Listeners

56,830 Listeners

5 Listeners

9,568 Listeners

11 Listeners

47,707 Listeners

50 Listeners

11 Listeners

465 Listeners

19 Listeners

0 Listeners